Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Merger Momentum | Neuronetics' merger with Greenbrook TMS shows early success, with significant synergies realized and expanded market presence driving growth potential |
Financial Resilience | Despite high Q1 cash burn, Neuronetics projects cash flow breakeven by Q3 2025 and maintains a healthy current ratio of 2.44 |
Strategic Expansion | SPRAVATO rollout and Brain Music Programming initiatives poised to boost revenue, with potential for adolescent indication coverage opening new markets |
Market Outlook | Analysts set $7.00 price target, reflecting optimism in Neuronetics' growth trajectory amid competitive neurohealth solutions landscape |
Metrics to compare | STIM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSTIMPeersSector | |
---|---|---|---|---|
P/E Ratio | −4.5x | −3.9x | −0.5x | |
PEG Ratio | −0.48 | −0.10 | 0.00 | |
Price/Book | 8.1x | 3.9x | 2.6x | |
Price / LTM Sales | 2.0x | 3.8x | 3.2x | |
Upside (Analyst Target) | 110.2% | 26.1% | 38.8% | |
Fair Value Upside | Unlock | −2.3% | 5.4% | Unlock |